ABOUT US

FIRST HEALTH PHARMACEUTICALS B.V.

First Health Pharmaceuticals B.V. is a biotech company with its main offices in Amsterdam, the Netherlands. Considering the groundbreaking nature of the RNA Helicase targeting technology, developed by our group, and the vast array of pathogens and malignancies that is targeted by our compounds, it will come as no surprise that many research groups worldwide, directly or indirectly, participated in the research in our field of interest. Some of these collaborations are based on a joint development agreement but most academic groups performed efficacy tests related to pathogens that fit their field of research purely for academic reasons. Our research group is the only one in the world that developed a large portfolio of small molecule DDX3 Helicase inhibitors, for use both as  antivirals and anti tumor agents. As such, many highly specialised research groups around the world are interested in testing our compounds, in order to gain more insight in the complex cellular RNA helicase biochemistry.

FIRST HEALTH GROUP

  • First Health Pharmaceuticals B.V. – fully owned by the First Health Capital investment foundation
  • First Health Capital – Investment Organisation and Holding of the First Health Group,
  • First Health Participations – gives access to First Health stocks to private investors.
  • First Health United – Independent Nonprofit Organisation (NPO) – receives donations and royalty-free access to First Health IP for Developing World.

FIRST HEALTH UNITED

First Health United is an Amsterdam-based non-profit organization, founded with the purpose to promote life science R&D for the benefit of humanity in general. It is a fully independent spin off of the company First Health Pharmaceuticals, who transferred the largest part of its antivirus development pipeline to the First Health United non-profit organization. After the foundation of the First Health Capital investment fund and the First Health Pharmaceuticals company, it was decided that a substantial percentage of all future revenues resulting from the DDX3 RNA Helicase antivirus and anti-tumour agents would be redirected towards a dedicated non-profit organization.

CONTACTS

You can visit us in our offices in Amsterdam, but please make an appointment because with many collaborations around the world, we travel extensively.

Science Park 406
1098XH Amsterdam
The Netherlands
Business Register of Amsterdam: 63003821
VAT: NL 855049832B01

For inquiries regarding the activities of First Health Capital, First Health United or First Health Participations, please write to:

Your Name (required)

Your Email (required)

Subject

Your Message

By using this form you agree with the storage and handling of your data by this website.